Overhaul could cut UK brand prices 20%
This article was originally published in Scrip
Prices of branded medicines used in the UK could undergo cuts of between 10% and 20%, according to a government consultation on proposals for changing the pricing of drugs used on the National Health Service.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.